US-based clinical stage biopharmaceutical company Peregrine Pharmaceuticals has started the patient enrolment in its SUNRISE trial, a pivotal Phase III study designed to evaluate the safety, tolerability and efficacy of bavituximab plus docetaxel in patients with second-line non-small cell lung cancer (NSCLC).

SUNRISE (Stimulating ImmUne RespoNse thRough BavItuximab in a PhaSE III Lung Cancer Study) will evaluate bavituximab plus docetaxel versus docetaxel plus placebo in approximately 600 patients at more than 100 clinical sites worldwide.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

SUNRISE, a global, randomised, double-blind, placebo-controlled clinical study, will enrol patients at leading oncology centres in the US.

"We anticipate that in executing our global plan we can enroll the majority of patients in this trial from the United States and Western Europe."

Patients with Stage IIIb/IV non-squamous, NSCLC who have progressed after standard front-line treatment are eligible for enrolment and will be randomised into 1 of 2 treatment arms.

All patients will receive up to six 21-day cycles of docetaxel (75mg/m2) plus weekly infusions of either bavituximab (3mg/kg) or placebo until progression of toxicity. The primary endpoint of the trial will be overall survival.

According to the company, the design of the SUNRISE trial was based on the compelling Phase II data that demonstrated encouraging improvement in overall survival in patients with second-line NSCLC.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, peer-reviewed published data supported that bavituximab and docetaxel share highly compatible mechanisms of action that hold promise for improved patient outcomes.

Peregrine CEO Steven King said: "As part of our plan to provide patient and physicians with the necessary information regarding this trial, today we launched the SunriseTrial.com web portal to serve as a gateway for trial parameters and additional resources.

"We anticipate that in executing our global plan we can enrol the majority of patients in this trial from the United States and Western Europe."